KENDRA EVANS: Open Payments
NPI 1285387555 · SHEFFIELD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,008 in 107 payments from 11 companies in 2025. Trend: 2023 $1,358 · 2024 $1,767 · 2025 $2,008
Food & beverage: $2,008
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $439 |
| Madrigal Pharmaceuticals | 11 | $273 |
| Ardelyx, Inc. | 11 | $245 |
| Phathom Pharmaceuticals, Inc. | 12 | $237 |
| Regeneron Healthcare Solutions, Inc. | 8 | $199 |
| Janssen Biotech, Inc. | 11 | $198 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $154 |
| Lilly USA, LLC | 4 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Gilead Sciences, Inc. | 1 | $28 |
Products named: REZDIFFRA, IBSRELA, VOQUEZNA, DUPIXENT, TREMFYA, RINVOQ, XIFAXAN, SKYRIZI.
Industry payments across AL — which companies pay providers there.
